Immutep Announces First Participant Dosed In Phase I Study Of IMP761
Immutep Announces First Participant Dosed In Phase I Study Of IMP761
- IMP761 is designed to enhance the "brake" function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseases
- Safety data from this first-in-human study anticipated by year-end and pharmacokinetics and pharmacodynamics data in first half CY2025
- IMP761旨在增强t细胞上的LAG-3的“刹车”功能，以恢复免疫系统的平衡，解决许多自身免疫性疾病的根本原因。
- 第一例人体试验的安全数据预计于年底公布，药物动力学和药物动力学数据将在2025年上半年公布。
SYDNEY, AUSTRALIA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first participant has been successfully dosed in the first-in-human Phase I trial of IMP761. This first-in-class agonist LAG-3 antibody is designed to restore balance to the immune system by enhancing the "brake" function of LAG-3 to silence dysregulated self-antigen-specific memory T cells that cause many autoimmune diseases.
澳洲悉尼，2024年8月14日（环球新闻社） - 生物技术公司Immutep Limited（（ASX：IMM，纳斯达克：IMMP）（“Immutep”或“公司”）宣布，在IMP761的首个一期人体试验中成功给第一名参与者注射了这种首创性LAG-3激动剂抗体，旨在通过增强LAG-3的“刹车”功能来平衡免疫系统，使失调的特异性自身抗原记忆t细胞沉默，以治疗许多自身免疫疾病。